Blood Test May Guide Prostate Cancer Therapy

(MedPage Today) -- Tumor cell make-up predicts response to hormonal agents
Source: MedPage Today Urology - Category: Urology & Nephrology Source Type: news

Related Links:

(MedPage Today) -- Patient preference assessment tool aligns with pros and cons of prostate cancer therapies
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
Authors: Zhao L, Zhou S, Gustafsson JÅ Abstract Nuclear receptors (NRs) are transcription factors actively involved in many aspects of human physiology and pathology, serving as sensors of stimuli, master regulators of downstream molecular events and hubs governing complex gene regulatory networks. The importance of various members of the NR superfamily in cancer has led to substantial efforts to target them therapeutically. Notably, drugs that block the action of estrogen receptor alpha (ERα) in patients with ERα+ breast cancer or the androgen receptor (AR) in prostate cancer patients have provid...
Source: Endocrine Reviews - Category: Endocrinology Tags: Endocr Rev Source Type: research
Conclusion: The study did not support an overall effect of postdiagnosis low-dose aspirin use on prostate cancer mortality. However, results for extended exposure periods suggest that low-dose aspirin use might be inversely associated with prostate cancer mortality after 5 years from cancer diagnosis. Primary Funding Source: Danish Cancer Society. PMID: 30831581 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Tags: Ann Intern Med Source Type: research
Publication date: Available online 1 March 2019Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Nada Zabaiou, Allan Fouache, Amalia Trousson, Julio Buñay-Noboa, Geoffroy Marceau, Vincent Sapin, Ahmed Zellagui, Silvère Baron, Mesbah Lahouel, Jean-Marc A. LobaccaroAbstractAntiandrogens have a peculiar place in the treatment of metastatic prostate cancer by blocking the androgen receptor (AR). Unfortunately, aggressive tumors could rapidly develop into a castration resistant state. It is therefore essential to look for new molecules that are more effective, affecting not only the andro...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
VIENNA - PET/MRI with the radiopharmaceutical gallium-68 (Ga-68) prostate-specific...Read more on AuntMinnie.comRelated Reading: Ga-68 PSMA-11 PET/MRI benefits prostate cancer patients Ga-68 PSMA-11 PET/MRI advances prostate cancer detection Gallium-labeled PET tracer could advance cancer detection SNMMI letter urges FDA to ease shortage of gallium-68 SNMMI: Early prostate cancer therapy extends lives
Source: Headlines - Category: Radiology Source Type: news
UCLA scientists have developed a new method to quickly screen hundreds of drugs in order to identify treatments that can target specific tumors.The approach could help scientists understand how a person ’s tumor would respond to a certain drug or drug combination, and it could help guide treatment decisions for people with rare and hard-to-treat cancers. Apaper detailing the new technique was published in Communications Biology.“We always focus on how we need new and better drugs to treat cancer,” said Alice Soragni, the senior author of the study and a scientist at the UCLA Jonsson Comprehensive Can...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
A shorter radiotherapy protocol for treating prostate cancer is comparable...Read more on AuntMinnie.comRelated Reading: ASTRO: AI's rad therapy future is in predicting outcomes ASTRO: SBRT works well for less risky prostate cancer ASTRO releases new prostate radiation therapy guideline SNMMI: Early prostate cancer therapy extends lives Hypofractionated RT works for prostate cancer
Source: Headlines - Category: Radiology Source Type: news
Abstract The evolution of therapeutic resistance is a major cause of death for cancer patients. The development of therapy resistance is shaped by the ecological dynamics within the tumor microenvironment and the selective pressure of the host immune system. These selective forces often lead to evolutionary convergence on pathways or hallmarks that drive progression. Thus, a deeper understanding of the evolutionary convergences that occur could reveal vulnerabilities to treat therapy-resistant cancer. To this end, we combined phylogenetic clustering, systems biology analyses, and molecular experimentation to ident...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Med Source Type: research
Abstract Both cancer and therapies used in the treatment of cancer can have significant deleterious effects on the skeleton, increasing the risks for both bone loss and fracture development. While advancements in cancer therapies have resulted in enhanced cancer survivorship for patients with many types of malignancies, it is increasingly recognized that efforts to reduce bone loss and limit fractures must be considered for nearly all patients undergoing cancer therapy in order to diminish the anticipated future skeletal consequences. To date, most studies examining the impact of cancer therapies on skeletal outco...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Br J Clin Pharmacol Source Type: research
CONCLUSION: This study demonstrates a systematic method to select questions on adverse events for a PRO questionnaire in a specific cancer population receiving oncologic treatment. The present study reveals that audit of patient files and patient interviews in our setting only add little to the information on adverse events obtained from FDA, EMA and RCT. The obtained questionnaire was found useful and acceptable by patients. PMID: 30702003 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Hormones | Prostate Cancer | Urology & Nephrology